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ABSTRACT
We have reported that chaperone-rich cell lysate (CRCL) is an effective anticancer vaccine in immunocom-
petent mice. In this study, we explored the therapeutic applicability of CRCL in the context of syngeneic
hematopoietic cell transplantation (HCT) to treat preexisting leukemia. Our results demonstrate that tumor
growth is significantly delayed in mice receiving syngeneic HCT from 12B1 tumor CRCL-immunized donors
compared with animals receiving HCT from nonimmunized donors. CRCL immunization after immune HCT
further hindered tumor growth when compared with immune HCT without posttransplantation vaccination.
The magnitude of the immune response was consistent with the antitumor effects observed in vivo. Rechal-
lenge of surviving mice with 12B1 or A20 cells in opposite groins confirmed that mice had developed long-term
tumor-specific immunity against 12B1 tumor cells. In addition, we documented that both T cells and natural
killer cells contributed to the antitumor effect of CRCL vaccination, because depletion of either subset
hampered tumor growth delay. Thus, our results indicate that CRCL is a promising vaccine capable of
generating specific immune responses. This antitumor immunity can be effectively transferred to a host via
HCT and further enhanced after HCT with additional tumor CRCL immunizations.
© 2006 American Society for Blood and Marrow Transplantation
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(NTRODUCTION
Allogeneic bone marrow transplantation (BMT) is
he only curative treatment for chronic myelogenous
eukemia (CML) [1-3]. However, this therapy is gen-
rally limited to patients with matched donors and is
sually not recommended for individuals over the age
f 50 years because of the high risk of developing
evere graft-versus-host–related complications. In con-
rast, autologous BMT for hematologic malignancies
s associated with less toxicity and can be successfully
sed for elderly patients and those unable to ﬁnd
atched donors [4]. Nevertheless, autologous BMT is
urrently not recommended for patients with CML
ecause of the unacceptably high relapse rates. Re-
apse results in part from residual bcr-abl cells in the
utologous graft and from the absence of a graft-
ersus-tumor effect [4,5]. Hence, efforts to augment
ost antitumor immunity in autologous BMT may
rovide a means to overcome leukemia relapse [6-9]. l
B&MTdoptive transfer of autologous antigen-speciﬁc T
ells from immunized hosts and/or active immuniza-
ion after BMT is being explored in humans [10,11]
nd studied in animal models [7,8,12-14].
We have previously reported that in numerous
nimal models, tumor-derived chaperone-rich cell ly-
ate (CRCL) that contains heat shock proteins (HSPs)
0 and 90, glucose regulate protein (GRP)94/glyco-
rotein (gp)96, and calreticulin can generate tumor-
peciﬁc T-cell responses and protective antitumor im-
unity [15-20]. Tumor-derived CRCL constitutes an
ffective and abundant source of autologous tumor
ntigens, and, by virtue of its adjuvant properties,
RCL stimulates dendritic cells to mature and secrete
nterleukin 12 [19].
To investigate the effect of CRCL vaccination
n an autologous hematopoietic cell transplantation
HCT) setting, we used an aggressive bcr-abl murine
eukemia, 12B1, that is resistant to total body irradi-
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2tion (TBI). We examined whether peritransplanta-
ion vaccination of mice with CRCL can be used
ffectively. Tumor growth was signiﬁcantly reduced
n mice receiving immune HCT compared with mice
eceiving HCT from nonimmunized donors. Addi-
ional CRCL vaccination in the early post-HCT
eriod further delayed tumor growth. This therapy
esulted in the activation of both tumor-speciﬁc
cells and natural killer (NK) cells. Peritransplan-
ation vaccination with CRCL should be well tol-
rated and therefore may have applications in the
utologous stem cell transplant setting for hemato-
ogic malignancies.
ATERIALS AND METHODS
umor Cell Lines
12B1 is a murine leukemia cell line derived by
etroviral transformation of BALB/c bone marrow
ells with the human bcr-abl (b3a2) fusion gene [21].
20 is a B-cell leukemia/lymphoma that arose spon-
aneously in an old (15 months) BALB/c mouse [22].
umor-Derived CRCL
Tumor-derived CRCL was generated as previ-
usly reported [16]. Brieﬂy, tumor was homogenized
n lysis buffer, and a 100 000g supernatant was ob-
ained and quantiﬁed (BCA assay; Pierce Endogen,
ockford, IL). The high-speed supernatant was sub-
ected to free-solution isoelectric focusing in a Bio-
ad Rotofor cell (Hercules, CA) for 5 hours at 15 W
f constant power. Twenty fractions were harvested,
nd each fraction was analyzed by sodium dodecyl
ulfate-polyacrylamide gel electrophoresis and West-
rn blot probing with speciﬁc antibodies for the chap-
rones HSP60, HSP70, HSP72 (inducible form of
SP70), HSP90, gp96, and calreticulin. Fractions
rom free-solution isoelectric focusing that contained
ubstantial amounts of the above chaperone proteins,
s determined by sodium dodecyl sulfate-polyacryl-
mide gel electrophoresis and Western blotting, were
ooled and dialyzed stepwise out of urea and deter-
ents. Pooled fractions were then concentrated using
entricon devices (Millipore, Bedford, MA). Deter-
ents were removed by passage over an Extractigel
atrix (Pierce Endogen). The fractions were recon-
tituted in phosphate-buffered saline (PBS), quantiﬁed
s described previously, and stored at 70°C until use.
ice
Female BALB/c (H-2d) mice that were 6 to 10
eeks old (Harlan Sprague Dawley, Indianapolis, IN)
ere used for the experiments. The animals were
oused in microisolator cages in a dedicated patho-
en-free facility and cared for according to the Uni- b
76ersity of Arizona Institutional Animal Care and Use
ommittee guidelines.
n Vivo HCT Experiments
On day 7, 6- to 8-week-old BALB/c mice were
njected subcutaneously (SC) with 1  104 (10-fold
he lethal dose) viable 12B1 cells. Tumor-bearing
ice were given 900 cGy of TBI on day 1 by using
cobalt 60 radiation source at a rate of 100 cGy/min.
onor bone marrow cells and splenocytes were har-
ested from syngeneic mice receiving no immuniza-
ion or 20 g of 12B1 CRCL SC 5 and 11 days
reviously. After lysing the red cells with ammonium
hloride potassium (ACK) lysing buffer, 2  107 bone
arrow cells and 5  107 splenocytes were injected
on day 0) intravenously in a volume of 0.2 mL of PBS
nto the tail vein of tumor-bearing recipients. The
nimals that received transplants were maintained in
terile microisolator cages and received sterile food
nd water. The overall transplant-related mortality
as 3%. Some HCT recipients also received post-
ransplantation vaccinations with 20 g of 12B1
RCL on days1 and6 (immune HCT CRCL).
ontrol animals consisted of mice injected with 104
2B1 cells without HCT (no HCT). In cell-depletion
xperiments, bulk splenocytes from CRCL-immu-
ized donors were collected and subjected to negative
mmunoselection by using magnetic-activated cell-
orting microbeads and a pan–T-cell isolation kit
Miltenyi Biotec Inc, Auburn, CA). This procedure
ives rise to 2 effector populations: CD3 T cells and
D3 non-T cells. The purity of CD3 T cells was
92%, and the percentage of CD3 cells in CD3
on-T cells was 5%. The CD3 non-T cells con-
ain B cells, NK cells, dendritic cells, macrophages,
nd granulocytes. To evaluate whether T-cell deple-
ion inﬂuences the antitumor effects, mice were in-
ected with the CD3 non–T-cell population or
D3 T-cell population plus unfractionated bone
arrow cells from immunized donors (T immune
CT or T immune HCT). To verify the effect of
K cell depletion, some donor mice that received
RCL immunization were given anti-asialo GM1 on
ays 6, 4, and 1 before their spleens were har-
ested (NK immune HCT).
Tumor size was measured with calipers every
ther day once the tumors became palpable. Tumor
olume was calculated by using the formula length 
idth2  /6. Mice were killed when the tumor vol-
me reached 4000 mm3. Statistical comparisons in
ean tumor volumes between groups were performed
y using 1-way analysis of variance with Newman-
euls multiple comparison post hoc tests, the Kaplan-
eier product-limit method was used to plot survival,
nd the log-rank statistic was used to test differences
etween groups [23,24]. Mice that rejected their tu-
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CRCL Vaccine in BMT
Bors were rechallenged with 3 103 12B1 or 106 A20
eukemia cells injected into the left or right groin 11 to
7 weeks after the ﬁrst challenge. As controls, age-
atched naive mice were given the same dose of 12B1
r A20 cells at the same time, and tumor growth was
onitored.
The immune reconstitution of mice after HCT
as determined by cell-surface staining of splenocytes
ith (anti-CD3, anti-CD4, and anti-CD8) speciﬁc
ouse antibodies (PharMingen, San Jose, CA) and
as analyzed by ﬂow cytometry (FACScan; Becton
ickinson, San Jose, CA). The number of splenocytes
as enumerated by trypan blue exclusion and reported
s the mean cell yield.
n Vitro Assays
For all in vitro assays, the mice were manipulated
n the same way as in the in vivo tumor growth
xperiments except that they had not been inoculated
ith 12B1 before HCT. Eight weeks after the HCT,
plenocytes were harvested and assessed for prolifer-
tion, interferon (IFN)– production, and cytolytic
ctivity.
For proliferation assays, the splenocytes were se-
ially diluted and cultured in triplicate wells for 4 days
n the presence or absence of 12B1 CRCL (10 g/mL)
ollowed by an 18-hour pulse with [3H]thymidine
1 Ci per well; 0.037 MBq) as previously described
15]. Cells were harvested by using a 96-well Packard
ell harvester, and radioactivity was measured on a
-counter (Packard Biosciences, Meriden, CT). Cell
roliferation was expressed as counts per minute (CPM)
f each experimental group stimulated with 12B1
RCL minus the background CPM in the absence of
2B1 CRCL stimulation. Differences of CPM be-
ween groups were compared by analysis of variance.
For the IFN- production assay, splenocytes (1 
06/mL) were cultured in 24-well plates in the pres-
nce or absence of 12B1 CRCL (10 g/mL). The
upernatants were collected 48 hours later, and IFN-
as determined by enzyme-linked immunosorbent as-
ay (R&D Systems, Minneapolis, MN).
Chromium 51 release assays were performed as de-
cribed previously [25]. Splenocytes (2  106/mL) were
timulated with 12B1 CRCL (10 g/mL) and cultured
or 5 days. Interleukin 2 (20 U/mL) was added to the
ulture 72 hours later. Cytolytic activity against 12B1
nd YAC-1 was determined in a standard 4-hour chro-
ium 51 release assay at various effector-target ratios.
ytotoxicity was determined by the formula
% cytotoxicity (expmean cpm spon release mean cpm) ⁄
(max release mean cpm spon release mean cpm) 100
ne lytic unit was deﬁned as the number of effectors
equired to lyse 30% of targets, and cytotoxicity was
resented as lytic units per 106 effector cells [26]. 1
B&MTESULTS
RCL Immunization Delays Tumor Growth in the
CT Setting
We have previously described 12B1 as an aggres-
ive leukemia: the lethal dose after SC injection is 103
ells [19,25]. SC inoculation of 104 cells (10-fold the
ethal dose) induces palpable tumors at a median time
f 10 days with bcr-abl 12B1 cells inﬁltrating the
pleen, lymph nodes, and bone marrow of tumor-
earing mice. To evaluate whether TBI followed by
CT is curative, BALB/c mice received 104 12B1
ells SC on day 7, a myeloablative dose of TBI (900
Gy) on day 1, and HCT on day 0. Because murine
one marrow is a poor source of lymphocytes, spleno-
ytes were added to more closely mimic human autol-
gous peripheral blood stem cell transplantation. We
ound that TBI followed by HCT delayed tumor
rowth (Figure 1) but extended the median survival
ime by only 6 days and failed to cure any mice of
eukemia.
We have previously reported that 12B1-tumor
RCL immunization of immunocompetent mice was
ffective in suppressing tumor growth [16,18-20,26].
n this study, we examined whether CRCL vaccina-
ion would provide a therapeutic advantage in a syn-
eneic transplantation setting. Because 12B1-bearing
ice die at a median time of 13 days after HCT (20
ays from tumor induction), it was necessary to im-
unize mice in the ﬁrst week after HCT, which
learly was not an optimal time to stimulate an im-
une response because CD4 and CD8 lympho-
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igure 1. Active immunization with CRCL in the early reconsti-
ution period after HCT. Mice (8 per group) bearing 6-day 12B1
umors received either no treatment (no HCT) or TBI (day 1)
ollowed by HCT (day 0) from nonimmunized donors. HCT con-
isted of 2  107 bone marrow cells plus 5  107 splenocytes. HCT
ecipients were vaccinated with 12B1 CRCL (HCT  CRCL) or
BS as control (HCT) on days 1 and 6 after HCT. Tumor
rowth was delayed in HCT groups regardless of post-HCT vac-
ination (either mock or CRCL vaccination) compared with the
o-HCT group (day 23: P  .001, HCT versus no HCT). Active
accination after HCT did not affect tumor growth (P 
 not
igniﬁcant; HCT  CRCL versus HCT). Representative data from
of 3 experiments are shown. Error bars represent SEM.
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2ytes were only beginning to reconstitute (Table 1).
ice were vaccinated on days 1 and 6 after HCT
ith 12B1-derived CRCL injected SC into the groin
pposite the site of tumor implantation and were then
onitored for tumor growth. Not surprisingly, there
as no difference in tumor growth velocity between
he 12B1 CRCL–vaccinated and PBS control mice
Figure 1), thus conﬁrming that vaccination with
RCL during the early reconstitution period after
CT does not stimulate an immune response sufﬁ-
ient to affect tumor progression.
We next examined whether tumor-speciﬁc immu-
ity generated in BALB/c donors can be adoptively
ransferred to HCT recipients and whether this can be
urther enhanced by CRCL vaccination after HCT.
onor BALB/c mice were immunized with CRCL 11
nd 5 days before their bone marrow and spleens were
arvested. HCT recipients of bone marrow and
plenocytes from nonimmunized (HCT) or immu-
ized (immune HCT) donors were vaccinated with
RCL (or PBS as control) on days 1 and 6 after
CT and monitored for tumor growth. Immune
CT recipients had signiﬁcantly delayed tumor growth
P  .05, HCT versus immune HCT; Figure 2).
RCL immunization after immune HCT further
ampered tumor growth when compared with im-
une HCT without posttransplantation vaccination
P  .05, immune HCT versus immune HCT 
RCL; Figure 2). Although we did not see apparent
umor regressions after an initial growth period, some
umors in the immune HCT  CRCL group seemed
table for some time. All mice in the no-HCT and
CT groups developed tumors, whereas 2 mice in the
mmune HCT group and 3 of 8 mice in the immune
CT  CRCL group rejected their tumors. These
ice were followed up for 60 days after tumor in-
culation. Taken together, these results indicate that
retransplantation antitumor immunity generated by
RCL vaccination can be effectively transferred to
CT recipients. In addition, CRCL vaccination, even
hen given during the early reconstitution period, can
able 1. T-Cell Reconstitution after Hematopoietic Cell
ransplantation (HCT)
Time after
HCT
Splenocytes CD4 T Cells CD8 T Cells
106 %* 106 %† 106 %‡
Week 1 10.0 11.9 0.5 1.9 0.3 2.4
Week 2 50.5 58.7 2.4 9.2 1.0 7.9
Week 3 57.0 65.2 6.4 22.9 2.7 22.4
Week 5 94.0 92.2 21.5 65.8 6.1 43.4
Percentage of total splenocytes compared with age-matched un-
treated controls.
Percentage of CD4 T cells compared with age-matched un-
treated controls.
Percentage of CD8 T cells compared with age-matched un-
treated controls.urther delay tumor growth. f
78ice Surviving after Immune HCT Have
ong-Term Tumor-Specific Immunity
To evaluate whether surviving mice had devel-
ped long-term tumor-speciﬁc immunity, we rechal-
enged survivors (immune HCT and immune HCT
RCL groups) from the experiments in Figure 2 (11
o 17 weeks after HCT) with a 3-fold lethal dose of
2B1 (3  103) and 1  106 A20 B-cell leukemia cells
C in opposite groins. Ten (83.3%) of 12 mice re-
ected 12B1 challenge, whereas only 3 (25%) of 12
ice rejected A20 leukemia, thus conﬁrming that im-
unity was long lasting and tumor speciﬁc (Figure 3).
n Vitro Assays Demonstrate Persistent Immune
esponses after HCT
To analyze the immune response generated by
RCL vaccination in the context of HCT, we evalu-
ted proliferation, IFN- production, and the cyto-
ytic activity of splenocytes harvested from posttrans-
lantation mice after complete cell reconstitution
fter HCT (8 weeks). 12B1 CRCL–stimulated spleno-
ytes from mice that received immune HCT followed
y post-HCT CRCL vaccination displayed a signif-
cantly higher proliferation compared with spleen
ells from naive HCT recipients (P  .005, immune
CT  CRCL versus HCT; Figure 4A). Splenocytes
rom immune HCT mice without posttransplantation
mmunization also showed substantial proliferation
P  .05, immune HCT versus HCT). The difference
etween immune HCT and immune HCT  CRCL
as also signiﬁcant (P  .05; Figure 4A). The num-
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igure 2. 12B1-speciﬁc immunity from immunocompetent donors
an be adoptively transferred via syngeneic HCT. Mice bearing
-day 12B1 tumors (8 per group) received no HCT (no HCT),
CT from nonimmunized donors (HCT), or HCT from 12B1
RCL immunized donors (immune HCT); some of the immune
CT mice received additional CRCL vaccination on days 1 and
6 after HCT (immune HCT  CRCL). HCT consisted of 2 
07 bone marrow cells plus 5  107 splenocytes. Immune HCT
elayed tumor growth when compared with HCT (day 23 onward:
 .05, immune HCT versus HCT). Immune HCT followed by
RCL immunization further delayed tumor growth (P  .05, im-
une HCT  CRCL versus immune HCT). Representative datarom 1 of 4 experiments are shown.
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Bers of T cells were comparable in the various groups
hown in Figure 4.
We then determined IFN- secretion by spleen
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n Figure 2 were rechallenged 11 or 17 weeks after the initial tumor inoc
s described in “Materials and Methods.” Age-matched naive mice (co
urvivors rejected rechallenge with 12B1, whereas all mice in the contr
ells grew in 75% of mice in both the survivor and control groups (P
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igure 4. In vitro assays demonstrated persistent immune responses
but did not receive tumor inoculation. Splenocyte proliferation, IF
CT as described in “Materials and Methods.” A, Splenocyte prol
roup stimulated with 12B1 CRCL minus the background CPM of
ersus HCT; P  .05, immune HCT  CRCL versus immune HC
001, immune HCT versus HCT; P  .0001, immune HCT  C
mmune HCT). C, Cytotoxicity against 12B1 targets by effector sp
otal lytic units per spleen. All assays were performed at least 3 times.
B&MTells cultured in the presence of 12B1 CRCL. In
itro–stimulated splenocytes from mice that received
mmune HCT or immune HCT  CRCL produced
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2igniﬁcantly higher amounts of IFN- when com-
ared with spleen cells from mice that received HCT
P  .001, immune HCT versus HCT; P  .0001,
mmune HCT  CRCL versus HCT; Figure 4B). In
ddition, splenocytes of mice that received immune
CT demonstrated signiﬁcantly higher cytolytic ac-
ivity against 12B1 compared with those from the
aive HCT or non-HCT groups. CRCL vaccination
fter immune HCT further increased the killing by
ffector cells (Figure 4C).
and NK Cells Contribute to the Adoptively
ransferred Antitumor Activity after
yngeneic HCT
To assess the contribution of lymphocyte sub-
opulations in the antitumor effects observed after
mmune HCT, depletion of speciﬁc cell subsets was
erformed either in vitro or in vivo. As mentioned
reviously, donor mice were immunized with CRCL
1 and 5 days before cells were harvested. T cells were
epleted or positively selected in vitro from spleno-
ytes of immunized donors and infused along with
one marrow to recipient mice 1 day after TBI (T or
 immune HCT, respectively). The numbers of
ells infused in the T and T immune HCT groups
ere adjusted so that they were similar to the total
umber of CD3 T cells or CD3 T cells in the
plenocyte preparation as immune HCT. Depletion of
cells from CRCL-immunized donors (T immune
CT) abrogated the effect of adoptive immunother-
py (Figure 5A). Mice that received T immune HCT
A
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igure 5. Both T and NK cells contribute to antitumor activity. A,
nd underwent transplantation with bone marrow from immunize
mmune HCT ) or an enriched CD3 T-cell population (T immu
CT or HCT from nonimmunized (HCT) or immunized (immun
ere used as controls. T-cell depletion abrogated the antitumor ef
urvival (P  .05, immune HCT versus HCT; P  .05, T immun
 immune HCT; P 
 not signiﬁcant, HCT versus T immune
ntraperitoneal injection with anti-asialo GM1 on days 6, 4, an
mmune HCT) or nondepleted (immune HCT) donor mice were t
ells signiﬁcantly impaired the antitumor effect of immune HCT (P
experiments are shown.ad a reduced antitumor effect when compared with 1
80hose that received bulk splenocytes. This could be
xplained in part by the absence of other effectors,
uch as NK cells or macrophages. To address the role
f NK cells, another donor group was treated in vivo
ith anti-asialo GM1 to deplete these cells after
RCL vaccination [27]. In vivo depletion of NK cells
lso resulted in reduced antitumor activity, thus con-
rming the active role of NK cells (Figure 5B). Over-
ll, these results indicate that both T and NK cells
ontribute to the adoptively transferred antitumor
ctivity.
To further analyze T and NK cell activity after
CT, we harvested spleen cells 8 weeks after mice
eceived immune HCT. These splenocytes were
estimulated in vitro with 12B1 CRCL for 5 days
nd then immunoselected into CD8 or CD8 ef-
ectors and tested against 12B1 for T-cell speciﬁcity
nd against YAC-1 for NK activity. Although the
ulk splenocytes of mice that received immune
CT displayed a comparable killing activity against
2B1 and YAC-1, the CD8 and CD8 subsets
howed different cytotoxicity against these targets.
ndeed, the CD8 splenocytes were 75-fold more
ffective in killing 12B1 targets than their CD8
ounterparts. In contrast, CD8 splenocytes were 3
imes more potent than CD8 T cells in killing
AC-1 (Figure 6). Therefore, although immune
CT increased both cytotoxic T lymphocyte and
K activity in vivo, tumor-speciﬁc cytotoxic T lym-
hocytes could be further expanded in vitro with
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the adoptive transfer, as indicated by the reduction in tumor-free
versus immune HCT; P 
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r T immune HCT). B, HCT donor NK cells were depleted by
the bone marrow and splenocytes from NK cell–depleted (NKneg
ed to recipient mice bearing 7-day 12B1 tumor. Depletion of NK
, NKneg immune HCT versus immune HCT). Cumulative data ofMice (
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BISCUSSION
We demonstrated that immunity generated by tu-
or-derived CRCL immunization in syngeneic HCT
onors can be effectively transferred to recipient mice
ia HCT. Adoptive transfer of CRCL immunity led to
ong-term tumor-free survival in a leukemia therapeu-
ic model. This immunotherapeutic strategy was used
or treatment of 12B1 leukemia that had been estab-
ished for 6 days: a standard therapeutic protocol of
BI followed by HCT was unable to cure any mice. In
ur model system, adoptive transfer of CRCL immu-
ity in the form of bone marrow and splenocytes from
mmunized donors (immune HCT) imparted a signif-
cant immunotherapeutic advantage over infusion of
he same cells from naive donors (HCT). Moreover,
doptive immunity could be further augmented by
ctive immunization with CRCL within 1 week after
CT, leading to long-term and speciﬁc protection
gainst 12B1, from which the CRCL originated. In
ivo priming of donors likely increased the percentage
f tumor-speciﬁc memory T cells in the T-cell pool
28]. T-cell or NK cell depletion from donor spleno-
ytes indicated that both lymphocyte populations con-
ributed to the observed antitumor effect. Given that
RCL is composed of HSPs, which have been dem-
nstrated to be capable of activating both the innate
nd adaptive immune systems [29-31], it is not sur-
rising that we detected increased NK activity after
RCL treatment. HSPs have consistently been re-
orted to activate NK cells by mechanisms that have
ot been well deﬁned [30-34].
12B1 is an extremely aggressive leukemia model
nd resembles CML in blast crisis, a stage that is
otoriously difﬁcult to treat. Because of the rapid
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Bulk splenocytes
CD8+ splenocytes
CD8- splenocytes
igure 6. Both cytotoxic T lymphocyte and NK activities were
nhanced in mice that received immune HCT. Mice received im-
une HCT as described in Figure 5. Eight weeks after HCT,
plenocytes were harvested and cultured 5 days in vitro. The cyto-
ytic activity of bulk splenocytes, immunoselected CD8 cells, and
D8 cells was assessed by chromium 51 release assay as described
n “Materials and Methods.” Lytic units per 106 effector cell subsets
bulk splenocytes, CD8 T cells, and CD8 cells separated from
ulk splenocytes) were calculated. Representative data from 1 of 3
xperiments are shown.rowth and metastatic spread of this tumor, it is very C
B&MTifﬁcult to treat established disease even when immu-
otherapy is combined with imatinib as early as day 2
fter tumor implantation [26]. Thus, the suppression
f the tumor and prolongation of survival with im-
une HCT with or without CRCL in this model is
oteworthy. Ours is not the ﬁrst study in which HSP
accines have been used in an HCT setting. Sato et al.
7] inoculated less aggressive A20 leukemia cells 10 days
fter BMT and started immunization of mice with
SP70 or gp96 before tumor induction. We have
reviously compared the CRCL vaccine with HSP70
nd gp96 in numerous tumor models, including A20,
nd have found it to be at least as potent as and in
ome cases superior to the puriﬁed individual HSP
accines [16,18]. In this study, we investigated the
rospect of augmenting immunity in recipients with
RCL immunization at the early reconstitution pe-
iod after HCT. From a quantitative aspect, the
mmune system generally returns to normal within
months after syngeneic BMT in mice, although the
ecovery of qualitative immune function may be
onger [35]. Because of the aggressive and metastatic
ature of 12B1, we were forced to immunize the HCT
ecipients within 1 week after HCT, a period in which
he immune system is incompletely reconstituted.
everal recent articles have demonstrated that ho-
eostasis-driven T-cell proliferation in reconstituted
ymphodepleted hosts improves the therapeutic efﬁ-
acy of tumor vaccines [9,36-38]. We did not observe
ny enhancement of antitumor effect with CRCL im-
unization at this early reconstitution period after
CT from naive donors, possibly because the immu-
ocompetence of mice that received lethal TBI was
ore severely impaired than the lymphopenia induced
y sublethal chemotherapy or low-dose TBI [39-41].
imilarly, Borrello et al. [42] reported that vaccination
f BALB/c mice 1 to 2 weeks after BMT with irradi-
ted A20 lymphoma cells genetically modiﬁed to
roduce granulocyte-macrophage colony-stimulating
actor failed to induce tumor rejection, whereas an
nti-A20 effect was observed when the same vaccina-
ion was performed 4 weeks after BMT.
Adoptive transfer of tumor-speciﬁc immunity
rom BMT donors has been used to treat malignant
isease in both animal and clinical studies [8,11-
4,43]. In these studies, however, investigators used
ell-deﬁned tumor antigens such as tumor-derived
diotype or inﬂuenza nucleoprotein [11-14,43]. Un-
ortunately, for most tumors there is a lack of well-
eﬁned, tumor-speciﬁc antigens. CRCL, which con-
ains at least 4 known immunogenic HSPs, as well as
otentially the entire repertoire of immunogenic pep-
ides derived from tumor, would be an appropriate
andidate for induction of tumor-speciﬁc immune re-
ponses [16,18-20,26].
In summary, we have shown that tumor-derived
RCL is an effective vaccine that can be used in
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2he transplantation setting to enhance antitumor re-
ponses. This study, along with our previous reports
hat CRCL vaccination is effective against a variety of
umors, supports the application of CRCL in stem cell
ransplantation for leukemia and other malignancies.
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